OrthoPediatrics (NASDAQ:KIDS – Get Free Report) is expected to release its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect OrthoPediatrics to announce earnings of ($0.2250) per share and revenue of $68.50 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 4:30 PM ET.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. The company had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. On average, analysts expect OrthoPediatrics to post ($1.14) EPS for the current fiscal year and ($0.83) EPS for the next fiscal year.
OrthoPediatrics Trading Down 0.8%
NASDAQ:KIDS opened at $24.50 on Friday. The firm has a market cap of $639.70 million, a P/E ratio of -14.58 and a beta of 0.99. OrthoPediatrics has a one year low of $14.42 and a one year high of $26.74. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.17 and a current ratio of 4.78. The firm has a 50-day simple moving average of $23.01 and a 200-day simple moving average of $20.20.
Analysts Set New Price Targets
A number of brokerages have issued reports on KIDS. BTIG Research reissued a “buy” rating and issued a $29.00 price target on shares of OrthoPediatrics in a report on Monday, September 14th. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, August 5th. Piper Sandler reissued an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Truist Financial upgraded shares of OrthoPediatrics to a “hold” rating in a research report on Thursday, October 1st. Finally, Needham & Company LLC raised their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.50.
View Our Latest Stock Analysis on OrthoPediatrics
Insider Activity at OrthoPediatrics
In other news, major shareholder Squadron Capital Llc sold 302,369 shares of the company’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the insider owned 6,201,764 shares of the company’s stock, valued at $130,299,061.64. This represents a 4.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder Jennifer Pritzker sold 302,369 shares of the firm’s stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the transaction, the insider directly owned 6,201,764 shares in the company, valued at $130,299,061.64. This trade represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,100,000 shares of company stock valued at $46,747,931 over the last quarter. Corporate insiders own 32.50% of the company’s stock.
OrthoPediatrics Company Profile
OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.
Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.
Featured Stories
- Five stocks we like better than OrthoPediatrics
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
